Literature DB >> 20300882

Characterization of a monoclonal antibody cell culture production process using a quality by design approach.

Brian Horvath1, Melissa Mun, Michael W Laird.   

Abstract

The goal of quality by design (QbD) in cell culture manufacturing is to develop manufacturing processes which deliver products with consistent critical quality attributes (CQAs). QbD approaches can lead to better process understanding through the use of process parameter risk ranking and statistical design of experiments (DOE). The QbD process starts with an analysis of process parameter risk with respect to CQAs and key performance indicators (KPIs). Initial DOE study designs and their factor test ranges are based on the outcomes of the process parameter risk ranking exercises. Initial DOE studies screen factors for significant influences on CQAs as well as characterize responses for process KPIs. In the case study provided here, multifactor process characterization studies using a scale-down model resulted in significant variation in charge heterogeneity of a monoclonal antibody (MAb) as measured by ion-exchange chromatography (IEC). Iterative DOE studies, using both screening and response surface designs, were used to narrow the operating parameter ranges so that charge heterogeneity could be controlled to an acceptable level. The data from the DOE studies were used to predict worst-case conditions, which were then verified by testing at those conditions. Using the approach described here, multivariate process parameter ranges were identified that yield acceptable CQA levels and that still provide operational flexibility for manufacturing.

Mesh:

Substances:

Year:  2010        PMID: 20300882     DOI: 10.1007/s12033-010-9267-4

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  4 in total

1.  A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma.

Authors:  E B Moran; S T McGowan; J M McGuire; J E Frankland; I A Oyebade; W Waller; L C Archer; L O Morris; J Pandya; S R Nathan; L Smith; M L Cadette; J T Michalowski
Journal:  Biotechnol Bioeng       Date:  2000-08-05       Impact factor: 4.530

2.  Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed.

Authors:  Wendy B Chaderjian; Edward T Chin; Reed J Harris; Tina M Etcheverry
Journal:  Biotechnol Prog       Date:  2005 Mar-Apr

3.  PDA technical report no. 42: Process validation of protein manufacturing. Parenteral drug Association.

Authors: 
Journal:  PDA J Pharm Sci Technol       Date:  2005 Sep-Oct

4.  Quality-by-design (QbD): effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940-04 segregation tester.

Authors:  Lin Xie; Huiquan Wu; Meiyu Shen; Larry L Augsburger; Robbe C Lyon; Mansoor A Khan; Ajaz S Hussain; Stephen W Hoag
Journal:  J Pharm Sci       Date:  2008-10       Impact factor: 3.534

  4 in total
  4 in total

1.  Digital Twins and Their Role in Model-Assisted Design of Experiments.

Authors:  Kim B Kuchemüller; Ralf Pörtner; Johannes Möller
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

2.  Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.

Authors:  Yoshinobu Konno; Yuki Kobayashi; Ken Takahashi; Eiji Takahashi; Shinji Sakae; Masako Wakitani; Kazuya Yamano; Toshiyuki Suzawa; Keiichi Yano; Toshio Ohta; Masamichi Koike; Kaori Wakamatsu; Shinji Hosoi
Journal:  Cytotechnology       Date:  2011-08-27       Impact factor: 2.058

3.  Modulating cell culture oxidative stress reduces protein glycation and acidic charge variant formation.

Authors:  Stanley Chung; Jun Tian; Zhijun Tan; Jie Chen; Na Zhang; Yunping Huang; Erik Vandermark; Jongchan Lee; Michael Borys; Zheng Jian Li
Journal:  MAbs       Date:  2019-01-03       Impact factor: 5.857

Review 4.  Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review.

Authors:  Sanjeev K Gupta; Pratyoosh Shukla
Journal:  Front Pharmacol       Date:  2017-07-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.